Overview

Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects

Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate the safety and tolerability of ILV-095 when it is given to individuals with moderate to severe chronic plaque psoriasis. Another purpose of the study is to observe how the drug enters the blood and tissues over time, how the body breaks down the drug and whether or not the body will develop an immune reaction (sensitivity) to the drug.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer